Financial Performance - Total revenues for Q3 2024 were $3.8 million, a net increase of approximately $2.5 million compared to $1.2 million for the same period in 2023, primarily driven by collaboration revenue from Roche[6] - Total revenues for the three months ended September 30, 2024, were $3,779,000, a 203% increase compared to $1,246,000 for the same period in 2023[21] - Collaboration revenues increased to $3,386,000 for the three months ended September 30, 2024, compared to $957,000 in the same period of 2023, representing a 254% growth[21] - Net loss attributable to Lineage for Q3 2024 was $3.0 million, or $0.02 per share, compared to a net loss of $7.1 million, or $0.04 per share, for the same period in 2023[11] - Net loss attributable to Lineage for the nine months ended September 30, 2024, was $15,336,000, an improvement from a net loss of $16,711,000 for the same period in 2023[22] Operating Expenses - Total operating expenses for Q3 2024 were $7.6 million, a decrease of $0.3 million compared to $7.9 million for the same period in 2023[7] - Total operating expenses for the three months ended September 30, 2024, were $7,619,000, a decrease of 4% from $7,951,000 in the same period of 2023[21] - R&D expenses for Q3 2024 were $3.2 million, a net decrease of approximately $0.6 million compared to $3.7 million for the same period in 2023[8] - Research and development expenses for the three months ended September 30, 2024, were $3,171,000, a decrease from $3,741,000 in the same period of 2023[21] - G&A expenses for Q3 2024 were $4.4 million, a net increase of $0.4 million compared to $4.0 million for the same period in 2023[9] Cash and Equity - Cash, cash equivalents, and marketable securities totaled $32.7 million as of September 30, 2024, expected to support operations into Q1 2026[6] - The company had cash and cash equivalents of $27,750,000 at the end of the period, down from $31,474,000 at the end of the previous year[22] - Cash used in operating activities for the nine months ended September 30, 2024, was $16,746,000, a reduction from $22,547,000 in the same period of 2023[22] - The company reported a net cash provided by financing activities of $14,123,000 for the nine months ended September 30, 2024, compared to $6,436,000 in the same period of 2023[22] - As of September 30, 2024, total shareholders' equity was $64,794,000, an increase from $62,023,000 as of December 31, 2023[20] Regulatory and Market Recognition - OpRegen received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for the treatment of geographic atrophy secondary to age-related macular degeneration[3] - Lineage was added to the 2024 Russell 3000 Index, indicating positive market recognition[1] Research and Development - ReSonance (ANP1) preclinical results were presented at the 59th Annual Inner Ear Biology Workshop, showcasing its potential for treating sensorineural hearing loss[4] - Loss from operations for Q3 2024 was $3.8 million, a decrease of $2.9 million compared to $6.7 million for the same period in 2023[9] - The weighted-average common shares used to compute basic and diluted net loss per common share increased to 188,835 for the three months ended September 30, 2024, from 174,868 in the same period of 2023[21]

Lineage Cell (LCTX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Since a changi ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Ioana Hone - Head of Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Conference Call Participants Hsuan-Cheng Kuo - B. Riley Securities Joseph Pantginis - H.C. Wainwright & Co., LLC Jack Allen - Robert W. Baird & Co. Michael Okunewitch - Maxim Group, LLC Operator Welcome to the Lineage Cell Therapeutic Second Quarter 2024 Conference Call. A ...

Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.04 per share when it actually produced a loss of $0.04, delivering no surprise. Over the last four quarters, the company has surpass ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol Name of exchange on which registered Common shares LCTX NYSE American LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number 001-12830 Lineag ...

Exhibit 99.1 LINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • 24 Month Visual Acuity Benefits from a Single Administration with OpRegen ® Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit • Supported OpRegen for Geographic Atrophy in Phase 2a Study in Collaboration with Roche and Genentech • Initiated Activities Under Recently Established Services Agreement with Genentech to Support Ongoing Development of OpRegen Program • OPC1 Clinical Stud ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Ioana Hone - Head, Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Conference Call Participants Jack Allen - Baird William Wood - B. Riley Joe Pantginis - H.C. Wainwright Michael Okunewitch - Maxim Group Sean McCutcheon - Raymond James Operator Welcome to the Lineage Cell Therapeutics First Quarter 2024 Conference Call. At this time, all part ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) California 94-3127919 (Stat ...

Exhibit 99.1 CARLSBAD, CA – May 9, 2024 - Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its first quarter 2024 financial and operating results and will host a conference call at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. - OPC1 Balance Sheet Highlights "The quarter was highlighted by significant milestones and data updates on our lead pr ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Ioana Hone - Head of IR Brian Culley - CEO Jill Howe - CFO Conference Call Participants Joe Pantginis - H.C Wainwright Jack Allen - Baird Kristen Kluska - Cantor Fitzgerald Mayank Mamtani - B. Riley Sean McCutcheon - Raymond James Michael Okunewitch - Maxim Group Operator Welcome to the Lineage Cell Therapeutics Fourth Quarter and Fiscal Year-End 2023 Conference Call. At this time, all ...